CA2433792A1 - Vaccin contre l'infection par la bacterie escherichia coli enterohemorragique - Google Patents

Vaccin contre l'infection par la bacterie escherichia coli enterohemorragique Download PDF

Info

Publication number
CA2433792A1
CA2433792A1 CA002433792A CA2433792A CA2433792A1 CA 2433792 A1 CA2433792 A1 CA 2433792A1 CA 002433792 A CA002433792 A CA 002433792A CA 2433792 A CA2433792 A CA 2433792A CA 2433792 A1 CA2433792 A1 CA 2433792A1
Authority
CA
Canada
Prior art keywords
ehec
composition
ruminant
escherichia coli
immunological adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002433792A
Other languages
English (en)
Other versions
CA2433792C (fr
Inventor
Andrew A. Potter
Brett Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2433792A1 publication Critical patent/CA2433792A1/fr
Application granted granted Critical
Publication of CA2433792C publication Critical patent/CA2433792C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes permettant de stimuler une réponse immune contre un antigène sécrété de Escherichia coli entérohémorragique (EHEC). Ces compositions renferment des surnageants de culture cellulaire de EHEC.
CA2433792A 2001-01-04 2002-01-03 Vaccin contre l'infection par la bacterie escherichia coli enterohemorragique Expired - Fee Related CA2433792C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25981801P 2001-01-04 2001-01-04
US60/259,818 2001-01-04
PCT/CA2002/000019 WO2002053181A1 (fr) 2001-01-04 2002-01-03 Vaccin contre l'infection par la bacterie escherichia coli enterohemorragique

Publications (2)

Publication Number Publication Date
CA2433792A1 true CA2433792A1 (fr) 2002-07-11
CA2433792C CA2433792C (fr) 2012-03-27

Family

ID=22986519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2433792A Expired - Fee Related CA2433792C (fr) 2001-01-04 2002-01-03 Vaccin contre l'infection par la bacterie escherichia coli enterohemorragique

Country Status (11)

Country Link
US (4) US7300659B2 (fr)
EP (2) EP2295075A1 (fr)
JP (3) JP2004516333A (fr)
AR (1) AR069722A1 (fr)
AU (1) AU2002218927B2 (fr)
BR (1) BR0206312A (fr)
CA (1) CA2433792C (fr)
ES (1) ES2446984T3 (fr)
MX (1) MXPA03006042A (fr)
NZ (1) NZ527322A (fr)
WO (1) WO2002053181A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101337A1 (fr) * 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Procédés et compositions comprenant des protéines bactériennes sécrétées de type iii pour l'immunisation par voie muqueuse d'animaux
WO2008025171A1 (fr) * 2006-08-31 2008-03-06 The University Of British Columbia Vaccins et procédés pour le traitement ou la prévention d'infections bactériennes par des espèces salmonella chez un sujet vertébré

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
AU2002218927B2 (en) * 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
CA2339436A1 (fr) * 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
AU2002241162A1 (en) * 2001-03-29 2002-10-15 Imperial College Innovations Limited Intimins in the prevention or treatment of infections:ii
WO2004050119A1 (fr) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccin contre escherichia coli enteropathogene et enterohemorragique
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
MXPA06004858A (es) 2003-10-31 2007-04-16 Univ British Columbia Factores de virulencia bacteriana y sus usos.
DE102005011894B4 (de) * 2005-03-15 2010-11-25 Qimonda Ag Schaltungsanordnung zum Erzeugen eines Synchronisiersignals
WO2008133659A2 (fr) * 2006-11-29 2008-11-06 Tufts University Mutants d'escherichia coli et leurs procédés d'utilisation
US9610333B2 (en) * 2008-07-11 2017-04-04 Tufts University Methods, compositions and kits for vegetative cell-based vaccines and spore-based vaccines
JP2012520878A (ja) * 2009-03-19 2012-09-10 ロサンゼルス ビオメドイカル リサーチ インストイトウテ アト ハルボル‐ユーシーエルエー メドイカル センテル ムコール菌症、及びその他の真菌疾患の治療のためのワクチン組成物、及び方法
WO2010115278A1 (fr) 2009-04-06 2010-10-14 University Of Saskatchewan Procédés et compositions pour traiter et prévenir une infection à escherichia coli produisant la toxine shiga
WO2011005587A1 (fr) * 2009-06-24 2011-01-13 University Of Dubuque Compositions de vaccin et procédés d'utilisation pour protéger contre des maladies infectieuses
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
CN103558377B (zh) * 2013-11-06 2016-04-13 湖北省农业科学院畜牧兽医研究所 一种肠出血性大肠杆菌o157:h7elisa抗体检测试剂盒及其使用方法
US9579370B2 (en) 2014-03-04 2017-02-28 The Board Of Regents Of The University Of Texas System Compositions and methods for enterohemorrhagic Escherichia coli (EHEC)vaccination
US10226520B2 (en) 2014-03-04 2019-03-12 The Board Of Regents Of The University Of Texa System Compositions and methods for enterohemorrhagic Escherichia coli (EHEC) vaccination
JP7354106B2 (ja) * 2017-12-04 2023-10-02 インターベット インターナショナル ベー． フェー． レプリコン粒子および油性アジュバントによるワクチン接種
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020051381A1 (fr) * 2018-09-05 2020-03-12 University Of Florida Research Foundation, Inc. Vaccin à base de salmonelle à immunité protectrice améliorée (piesv) contre brucella spp.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1605763A (en) 1926-11-02 Garment retainer
US3788315A (en) 1971-04-20 1974-01-29 S Laurens Disposable cutaneous transjector
US3853125A (en) 1971-10-05 1974-12-10 W Clark Disposable needleless injector
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
JPS5920226A (ja) * 1982-07-26 1984-02-01 Kitasato Inst:The 動物用ワクチンおよびその製造法
CA1247080A (fr) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Sequences d'acides amines ayant une activite antigenique
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5062830A (en) 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
EP0659086B1 (fr) * 1992-09-04 1998-11-11 The University of Saskatchewan Nouveaux vaccins bacteriens utilisant des souches vaccinales de bacteries pathogenes
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
WO1996040861A1 (fr) * 1995-06-07 1996-12-19 Biolog, Inc. Milieux de cultures microbiologiques permettant d'isoler et d'identifier des pathogenes enteriques, tels que e. coli et salmonella
FR2747394B1 (fr) 1996-04-15 1998-07-03 Rambach Alain Milieu de culture pour la mise en evidence des bacteries e. coli enterohemorragiques, et procede pour sa mise en evidence
CA2252372C (fr) 1996-04-23 2010-06-29 B. Brett Finlay Proteine associee a un escherichia coli pathogene
US5951998A (en) * 1997-02-18 1999-09-14 Idemitsu Materials Co., Ltd. Ascites-preventive agent and ascites-preventive method for broilers
AU1137399A (en) 1997-11-12 1999-05-31 University Of British Columbia, The Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene
US7208574B1 (en) * 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
GB9723945D0 (en) * 1997-11-12 1998-01-07 Nat Environmental Research Cou Tissue cement
AU2002218927B2 (en) * 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101337A1 (fr) * 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Procédés et compositions comprenant des protéines bactériennes sécrétées de type iii pour l'immunisation par voie muqueuse d'animaux
WO2008025171A1 (fr) * 2006-08-31 2008-03-06 The University Of British Columbia Vaccins et procédés pour le traitement ou la prévention d'infections bactériennes par des espèces salmonella chez un sujet vertébré

Also Published As

Publication number Publication date
US7300659B2 (en) 2007-11-27
WO2002053181A8 (fr) 2002-09-19
US20090068230A1 (en) 2009-03-12
US20020160020A1 (en) 2002-10-31
US20080145384A1 (en) 2008-06-19
JP2013151499A (ja) 2013-08-08
WO2002053181A1 (fr) 2002-07-11
EP1349570A1 (fr) 2003-10-08
US20140065188A1 (en) 2014-03-06
NZ527322A (en) 2005-07-29
US8586057B2 (en) 2013-11-19
AR069722A1 (es) 2010-02-17
EP1349570B1 (fr) 2013-11-20
JP2009132742A (ja) 2009-06-18
EP2295075A1 (fr) 2011-03-16
JP5322718B2 (ja) 2013-10-23
BR0206312A (pt) 2004-02-17
ES2446984T3 (es) 2014-03-11
JP2004516333A (ja) 2004-06-03
CA2433792C (fr) 2012-03-27
AU2002218927B2 (en) 2007-08-30
MXPA03006042A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
AR069722A1 (es) Vacuna contra escherichia coli enterohemorragica
AU3233795A (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
EP0120532B1 (fr) Vaccin contre Pseudomonas Aeruginosa à base d'exopolysaccharide mucoidique
EP0432203B1 (fr) Vaccins contre la legionellose et procedes pour leur production
Imatani et al. Production of inflammatory cytokines by human gingival fibroblasts stimulated by cell‐surface preparations of Porphyromonas gingivalis
Gilleland Jr et al. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model
DK0732937T4 (da) Ikke-toxisk slimhindeadjuvans
CA2132836A1 (fr) Immunisation par injection d'une unite de transcription genetique
CA2437899A1 (fr) Vaccin pour immunisation transcutanee contre la diarrhee du voyageur causee par l'etec
JP2009132742A5 (fr)
JP2004516333A5 (fr)
Confer et al. Recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE enhances commercial M. haemolytica vaccine-induced resistance against serotype 6 challenge
AU693864B2 (en) Antigenic preparation for treatment or prevention of helicobacter infection
CA2154063A1 (fr) Traitement de troubles gastroduodenaux associes a h. pylori
AU4788693A (en) P53 vaccine
Iovane et al. Role of Pasteurella multocida porin on cytokine expression and release by murine splenocytes
US4239749A (en) Neisseria gonorrhoeae vaccine
Cai et al. Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice
Irvin et al. Citrate-tris (hydroxymethyl) aminomethane-mediated release of outer membrane sections from the cell envelope of a deep-rough (heptose-deficient lipopolysaccharide) strain of Escherichia coli O8
Takahashi et al. Intranasal immunization of mice with recombinant protein antigen of serotype cStreptococcus mutans and cholera toxin B subunit
WO2001049319A8 (fr) Composition de prevention et de traitement des troubles allergiques
Gregory et al. IgA antibodies to oral and ocular bacteria in human external secretions
Groschup et al. Modified Feist broth as a serum-free alternative for enhanced production of protective antigen of Erysipelothrix rhusiopathiae
Lopez-Merino et al. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances
Kozuka et al. Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200103